Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
Altan M, Lopes G, Hiltermann TJN, Govindan R, Villaruz LC, Calvo E, Edelman MJ, Furqan M, Neal J, Felip E, Carlisle JW, Heymach JV, O'Cearbhaill RE, Zauderer M, Chisamore M, Corigliano E, Eleftheriadou I, Zajic S, Jenkins B, Goodison S, Suchindran S, Ramos-Hernandez N, Tarek N, Schoenfeld AJ. Altan M, et al. Among authors: villaruz lc. Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591. Online ahead of print. Clin Cancer Res. 2024. PMID: 39576208
Development, review, and activation of thoracic oncology investigator-initiated trials.
Gerber DE, Wynters CR, Prasad T, Schnel RK, Zhang S, Stinchcombe TE, Villaruz LC, Bauml JM, Iams WT, Patil T, Liu SV, Horn L, Hudak JM, Camidge DR. Gerber DE, et al. Among authors: villaruz lc. Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-3460. Online ahead of print. Clin Cancer Res. 2025. PMID: 39820484
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. Munster P, et al. Among authors: villaruz lc. Cancer Res Commun. 2023 Dec 19;3(12):2572-2584. doi: 10.1158/2767-9764.CRC-22-0461. Cancer Res Commun. 2023. PMID: 38115208 Free PMC article. Clinical Trial.
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Gentzler RD, Villaruz LC, Rhee JC, Horton B, Mock J, Hanley M, Kim K, Rudek MA, Phelps MA, Carducci MA, Piekarz R, Park KS, Bullock TN, Rudin CM. Gentzler RD, et al. Among authors: villaruz lc. Oncologist. 2023 Nov 2;28(11):1007-e1107. doi: 10.1093/oncolo/oyad221. Oncologist. 2023. PMID: 37555284 Free PMC article. Clinical Trial.
Tumor cell p38 inhibition to overcome immunotherapy resistance.
Luke JJ, Dadey RE, Augustin RC, Newman S, Singh KB, Doerfler R, Behr S, Lee P, Isett B, Deitrick C, Li A, Joy M, Reeder C, Smith K, Urban J, Sellitto L, Jelinek M, Christner SM, Beumer JH, Villaruz LC, Kulkarni A, Davar D, Poklepovic AS, Najjar Y, Zandberg DP, Soloff AC, Bruno TC, Vujanović L, Skinner HD, Ferris RL, Bao R. Luke JJ, et al. Among authors: villaruz lc. Res Sq [Preprint]. 2023 Aug 19:rs.3.rs-3183496. doi: 10.21203/rs.3.rs-3183496/v1. Res Sq. 2023. PMID: 37645831 Free PMC article. Preprint.
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).
Krishnamurthy A, Wang H, Rhee JC, Davar D, Moy RH, Ratner L, Christner SM, Holleran JL, Deppas J, Sclafani C, Schmitz JC, Gore S, Chu E, Bakkenist CJ, Beumer JH, Villaruz LC. Krishnamurthy A, et al. Among authors: villaruz lc. Cancer Chemother Pharmacol. 2025 Jan 22;95(1):27. doi: 10.1007/s00280-024-04745-6. Cancer Chemother Pharmacol. 2025. PMID: 39841295 Clinical Trial.
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.
Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, Liu G, Patel D, Liu SV, Montenegro GLB, Patil T, Nieva JJ, Herrmann A, Marrone KA, Lam VK, Schwartzman W, Dowell J, Villaruz LC, Miller KL, Weiss J, Sun F, Velcheti V, Camidge DR, Aggarwal C, Sun L, Marmarelis ME. Grady CB, et al. Among authors: villaruz lc. Pharmacoepidemiol Drug Saf. 2024 Dec;33(12):e70049. doi: 10.1002/pds.70049. Pharmacoepidemiol Drug Saf. 2024. PMID: 39586662 Free PMC article.
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Fortman D, Wang H, VanderWeele R, Evans T, Herman JG, Rhee J, Reyes V, McLaughlin B, Wozniak A, Somasundaram A, Mekhail T, Socinski MA, Schulze K, Villaruz LC. Fortman D, et al. Among authors: villaruz lc. Clin Lung Cancer. 2025 Jan;26(1):78-81. doi: 10.1016/j.cllc.2024.10.014. Epub 2024 Oct 30. Clin Lung Cancer. 2025. PMID: 39578170 Free article.
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Mansfield AS, et al. Among authors: villaruz lc. Lung Cancer. 2024 Sep;195:107928. doi: 10.1016/j.lungcan.2024.107928. Epub 2024 Aug 13. Lung Cancer. 2024. PMID: 39197359 Clinical Trial.
61 results